

HEALTH HORIZON DIAGNOSTICS

METROPOLIS HEALTHCARE LTD. EXTERNAL QUALITY ASSURANCE SERVICE (MHL EQAS PROGRAM)

FOR
UNACCEPTABLE RESULTS OF

SERUM CHLORIDE TEST



EQAS CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS

HEALTH HORIZON DIAGNOSTICS

Page 1 of 1

SR.	LIST OF DOCUMENTS		
NO			
01	Annexure: 01: Instrument service Report		
02	Annexure: 02: Internal Quality Control Data Date of		
	17/01/2023 & 30/01/2023		
03	Annexure: 03: Internal Quality Control BIO-RAD Value		
	Sheet Lot No. 26490, Level 01:26491 & Level 02: 26492		
04	Annexure: 04: Inter-Lab Comparison (ILC) Report		
05	Annexure: 05: MOU with NABL Accredited Lab for		
	Outsource Investigation		



FORMAT OF EXTERNAL QUALITY CONTROL/ PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS

ANNEXURE-01

HEALTH HORIZON DIAGNOSTICS

Type of Evaluation: External Quality Control / Proficiency Testing (PT) Sample
Other (Specify):
Evaluation Date: 25/01/2023
Investigation: Hematology Biochemistry Urine Serology Immunology
Other (Specify):
Unacceptable Analyte/ Parameter:
MHLEGAS Sample No:01 = chloride
MHLEGAS Sample No:01 = chloride Sample No:02 = chloride

Description/Error/Reason/Remark:

MHL EGAS Sample No: 01 - 3DI Z-Score = 3:55 Unaueptable

Sample No. 02 - 3DI Z-Score = 3:40 Unaueptable

Investigations (Root Cause Analysis):

Phase	Commonest Reasons			
Pre-Analytical Phase	1. Missed Test Requisition Form (TRF)			
	2. Incorrect sample identification			
	3. Incorrect sample tube			
	4. Sample from IV running area			
	5. Delay in sample transportation			
	6. Insufficient samples			
	7. Sample mix-ups			
	8. Tube broken in centrifuge			
	9. Wrong timing for Collection			
	10. Invalid Specimen: Haemolysed Sample, Lipemic Sample and Icteric Sample			
	11. Software errors			
Analytical Phase	Instrument not calibrated properly			
	2. Specimen mix-up			
	3. Inadequate specimen			
	4. Presence of interfering substances			
	5. Wrong analytical method			
	6. Lack of precision			
Post-Analytical Phase	1. Wrong patient identification			
	2. Report not legible			
	3. Report delayed			
	4. Transcriptional error			
	5. Specificity of the test not understood			
	6. Previous values are not available for comparison			



FORMAT OF EXTERNAL QUALITY CONTROL/ PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS

ANNEXURE-01

HEALTH HORIZON DIAGNOSTICS

Root Cause Analysis: We checked the Internal quality control of the date When EQAS was run, and found it within accept able range. Also the specimen handling was cross checked as per our asp "Handling proficiency Testing and External quality Assurance Sample (HHD-QSP/009/00)

Corrective Action: Corrective action taken on date 25/01/23 We checked Internal quality control record on date 17/01/2023, Tac result was within range. Also the preventive maintenance of the machin was done by service engineer.

Preventive Action: For the machine Easylyte Plus on date 30/01/2023 after maintenance Iac performed and it was within range.
We have established MOU with a NABL LAB and have planned ILC of serum chloride every three months.


Conclusion Serum chloride had a PT outlier and awardingly CAPA was taken.

Attachment (Attach result form and assessmen	t details):
Attached scan copy!	
1) Instrument Service Report	4) MOU with NABL Lab
2) Internal quality control data	s) Inter Lab Compan3ion(ILC)
on date 17/01/2023 & 30/01/2023	Data.
3) IGC BIO. RAD Value sheet	
Lot NO- 26490, Level-0126491	
Ltyel 02 - 26492	
Comment: Ni'	
Comment: N,'1 Shaupun 30/01/2	_023

Recorded By: Sign / Date (Laboratory Manager / Authorized trained person)

Comment: Satisfactory

Verified By: Sign / Date (Laboratory Director/Authorized trained person)



TRANSASIA®

TECHNICAL SERVICE RI	EPORT No. 15176	13	DATE: 30 01 23
CUSTOMER DETAILS	INSTRUMENT DETA		SERVICE STATUS
NAME: Health	MODEL: Forlyte		WARRANTY R&R
ADDRESS HIM 2413	SR, NO.: 56274		CHARGED CALL TYPE OF CALL
Diegvais	GALL DETAILS	Production of the Control of the Con	INSTALLATION
1 Pun	COMPLAINT RECD.	Marine Commission of the Party	P.M. VISIT THE HITTIV
TEL NO:	RESPONSE JOB COMPLETED		BREAKDOWN
NAME OF THE OPERATOR:	RESPONSE TIME		DOWN TIME:
PROBLEM REPORTED:		400 10	COUNTER READING:
OBSERVATIONS:	clonde los	3	
	found some	63	above
ACTION TAKEN;	Inde		•
	deplace parage	- C-69,1V	- clear 4 wray
Vic	due pump tubin	g cla	aned Solution
SITE CONDITION : LINE-NEUTRAL VO		(*117/a)1b.(*12	AND AND THE CONTRACTOR OF THE
BRAND OF REAGENT USED:	CITAL MARKET NEUTRAL-EART		BE FILLED IN BY CUSTOMER
FOLLOWING PARTS HAVE BEEN RE	EPLACED		ENTIVE MAINTENANCE CARRIED OUT FACTORILY.
NO. DESCRIPTION			T RECTIFIED & INSTRUMENT IS KING SATISFACTORILY
DESCRIPTION	QTY. COST TOTAL	PART	
		COM	MENTS (IF ANY):
			MENTS (IF ANY): Whatther
		SEAL	DATE CUSTOMER'S SIGNATURE
TOTAL Rs.		31	101/23 NAME:
INVOICE NO. :	DATE:		BRANCH H.O.
FOLLOW-UPACTION (Required if any)		RECEIVED	
		JOB CARD	
ENGINEER'S (APPLICATION SPECIAL)	must kewleron!		
NOTE: Parts recisced alle chargeable axcept du	ring warranty Period. Consumables like Parts rankeed due to necligance in open		CAMPIC STRUCTURE AND A PRINCIPAL STRUCTURE AND ADDRESS OF THE PRINCIPAL STRUCTURE AND ADDRESS OF
AT TRANSASIA, CUSTOMER SATISF PLEASE CONTACT: GENERAL MAN	ACTION IS OUR PRIME CONC AGER (TECHNICAL SERVICE),	MUMBAI. TI	L : 4030 9000
TRANSASIA BIO-MEDICALS LTI Head Office : Transasia House, 8, Chandiva			
Mumbai Toll Free No. 1800 103 8226	Whatsapp No. : 8451048434, SN ennel : Tel. : (044) 2822 7149	MS No. : 9212 Kolkata	433444 : Tel: (033) 2215 7839 Fax: 2215 803
Lucknow Tal. (0522) 443 0900 Pu		Dehl	: Tel. : (011) 2578 5451/2573 2223 d : Tel./Fax : (079) 02640 7030/4032 1903
faigur Tel: 93092 63147 Gu	wahati Tel.: 91369 50480 uttack Tel.: (0871) 232 4555	Bangalore	: Tel./Fax : (080) 2556 8044
Kochi Tel (0484) 402 0511 Hu			ZONE CO

www.transasia.co.in

ANNEXURE: 02

Internal Quality Control for Chloride Dale! - 17/01/2023

JAN-17-23; 10:26

ANALYSIS

PATLENT'S NAME

BIO-RAD.

Control-Level-02

SAMPLE 003

Na 123.6 K 5.72 CI 87.1

Na LO KHI CILO

BLOOD Na, K, CI mmol/L

(CORRELATED VALUES)

JAN-17-23; 10:27

Done By! - Checked By!
Sontoch

2012023

17/01/2023

Internal auculity control for chloride pate: - 30/01/2023

OPER FUNCTS

Na= 1.03X - 1.10 K = 1.02X - 0.24 CI= 0.99X + 3.46 BLOOD CORRELATION ON JAN-30-23; 12:23

Na/K/CI
5EAB
MODE OOA

OPER FUNCTS

SOL'N PURGE JAN-30-23; 12:25

CALIBRATION

CAL VALUES
Na 56.93 K 56.97 Ci 45.16
UAN-30-23; 12:29

ANALYSIS
PATIENT'S NAME

Pre-Run Cheek Value.

SAMPLE 003

Na 134.0 K 6.28 CI 96.8

Na LO K HI CI LO

BLOCO Na, K, CI mmol/L

(CORRELATED VALUES)

JAN-30-23; 12:40

ANALYSIS PATIENT'S NAME

SAMPLE 004

Na 128.4 K 5.81 CI 90.0

Na LO K HI CI LO


BLOOD Na, K, CI mmol/L

(CORRELATED VALUES)

JAN-30-23; 12:46

Done By! Santosh
30/01/2023

Cheeked 137! -Yhayllh 3010112023





Lyphochek® Assayed Chemistry Control Levels 1 and 2



C-310-5 Level 1 12 x 5 mL C-315-5 Level 2 12 x 5 mL 313X MiniPak 2 x 5 mL









26490

Level 1 26491 Level 2 26492



https://www.myeinserts.com/26490

INTENDED USE

Lyphochek Assayed Chemistry Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.

SUMMARY AND PRINCIPLE

The use of quality control materials is indicated as an objective assessment of the precision of methods and techniques in use and is an integral part of good laboratory practices. Multiple levels of control are available to allow monitoring of the test system's reliability.

For customers in Germany: Quality control materials are required for assessment of laboratory performance as described in the "Guideline for Quality Assurance of Medical Laboratory Examinations following the German Medical Association" (Rili-BÄK regulation).

REAGENT

This product is prepared from human serum with added chemicals, purified biochemical material (tissue extracts of human and animal origin), therapeutic drugs, stabilizers and preservatives. This product is provided in lyophilized form for increased stability.

STORAGE AND STABILITY

This product will be stable until the expiration date when stored unopened at 2 to 8°C.

<u>Reconstituted and Refrigerated:</u> After reconstituting and storing tightly capped at 2 to 8°C, this product will be stable as follows:

- All analytes: 7 days

Except:

- T3 (Free), Acid Phosphatase (Total) and Prostatic Acid Phosphatase (PAP): 3 days

Reconstituted and Frozen: When reconstituted and stored tightly capped at -10 to -20°C, this product will be stable as follows:

- All analytes: 30 days

Except:

- Tobramycin: 20 days

- T3 (Free): 10 days

Once thawed, do not refreeze this product. Discard the remaining material. This product is shipped under ambient conditions.

PROCEDURE

This product should be treated the same as patient specimens and run in accordance with the instructions accompanying the instrument, kit, or reagent being used.

Using a volumetric pipet or equivalent, reconstitute each vial with 5.0 mL of distilled or deionized water. Replace the stopper and allow this product to stand for approximately 20 minutes swirling occasionally.

Before sampling, gently swirl the vial several times to ensure homogeneity. If performing trace metal analysis, do not mix by inversion. After each use, promptly replace the stopper and return to the appropriate storage condition.

Dispose of any discarded materials in accordance with the requirements of your local waste management authorities. In the event of damage to packaging, contact the local Bio-Rad Laboratories Sales Office or Bio-Rad Laboratories Technical Services.

LIMITATIONS

1. This product should not be used past the expiration date.

2. If there is evidence of microbial contamination or excessive turbidity in the reconstituted product, discard the vial.

3. This product is not intended for use as a standard.

WARNING

Biological source material. Treat as potentially infectious.

Each human donor unit used to manufacture this product was tested as required by FDA accepted methods. Tests results were non-reactive or negative for evidence of infection due to Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV). This product may also contain other human source materials for which there are no approved tests. In accordance with good laboratory practice, all human source material should be considered potentially infectious and handled with the same precautions used with patient specimens.

Safety Data Sheet (SDS) available for professional users on www.bio-rad.com.

SPECIFIC PERFORMANCE CHARACTERISTICS

This product is a freeze-dried product manufactured under rigid quality control standards. To obtain consistent assay values, the control requires proper storage and handling as described.

ASSIGNMENT OF VALUES

The mean values and corresponding ±3SD ranges in the Assignment of Values Data Charts (available separately) were derived from replicate analyses and are specific for this lot of product. Data from Unity™ Interlaboratory Program are included in the determination of some ranges. The tests listed were performed by the manufacturer and/or independent laboratories using manufacturer supported reagents and a representative sampling of this lot of product. It is recommended that each laboratory establish its own acceptable ranges and use those provided only as guides. Laboratory established ranges may vary from those listed during the life of this control. [Customers in Germany have to follow the requirements as described in the Rili-BÄK regulation.] Variations over time and between laboratories may be caused by differences in laboratory technique, instrumentation and reagents, or by manufacturer test method modifications.

Unity™ Interlaboratory Program is a proprietary Bio-Rad software program holding more than 2 billion QC data points from thousands of laboratories.

INSTRUCTIONS FOR OBTAINING THE DATA CHARTS

The Data Charts are available through the Internet, at www.myeinserts.com/26490. Follow the directions at the website to receive email notifications of insert updates. Alternate methods for receiving data charts are available by contacting your local Bio-Rad Laboratories Office.



UNITED STATES. Bio-Rad Laborat imo Road, Irvine, CA 92618



FRANCE, Bio-Rad 3 boulevard Raymond Poincare, 92430 Marnes-la-Coquette Phone:(33) 1-4795-6000 / Fax:(33) 1-4741-9133





BIO-RAD

Bio-Rad Laboratories, Inc.

SWITZERLAND. Bio-Rad Laboratories AG Pra Rond 23, 1785 Cressier FR

Diagnostics Group

9500 Jeronimo Road Irvine, California 92618 (800) 854-6737 FAX (949) 598-1550 bio-rad.com/qualitycontrol

Technical Service: (800) 854-6737

Australia, Bio-Rad Laboratories Pty. Ltd., u1A, 62 Ferndell Street, South Granville, New South Wales 2142 • Phone +61 (2) 9914 2800 • Fax +61 (2) 9914 2888 Austria, Bio-Rad Laboratories Pty. Ltd., u1A, 62 Ferndeil Street, South Granville, New South Wales 2142 * Phone +61 (2) 9914 2808 * Phone +61 (2) 9914 2808 * Phone +63 (2) 99

Finland, Bio-Rad Finland Oy, Kutomotie 16 FI-00380, Helsinki • Phone +358 9 804 22 00

France, Bio-Rad Finland Oy, Kutomotie 16 FI-00380, Helsinki • Phone +358 9 804 22 00

France, Bio-Rad J, Soulevard Raymond Poincaré, 92430 Marnes-la-Coquette • Phone +33 (0) 1 47 95 60 00 • Fax +33 (0) 1 47 41 91 33

Germany, Bio-Rad Laboratories GmbH, Kapellenstraße 12, D-85622 Feldkirchen, Munich • Phone +49 (0) 89 31884 393 • Fax +49 (0) 89 31884 136

Gerece, Bio-Rad Laboratories GmbH, Kapellenstraße 12, D-85622 Feldkirchen, Munich • Phone +49 (0) 89 31884 393 • Fax +49 (0) 89 31884 136

Gerece, Bio-Rad Laboratories ME-FE, 2-4 Mesogion Ave. (Attens Tower) 11527 Ampelolik), Athens • Phone +30 210 7774396 • Fax +30 210 7774376

Hong Kong, Bio-Rad Laboratories Ltd., Unit 1101, 111/F DCH Commercial Centre, 25 Westlands Road, Quary Bay • Phone +85 2 2789 3300 • Fax +85 2 2789 1257

Hungary, Bio-Rad Laboratories India Pvt. Ltd., EMAAR Digital Greens, 9th Floor, Tower A- Sector 61 Gurugram-122 102, Haryana 122 015 • Phone +91 124 4029300 • Fax +91 124 2398115

Israel, Bio-Rad Laboratories Ltd., 14 Homa Street, New Industrial Area, Rishon Le Zion 76150 • Phone +972 3 963 6025 • Fax +972 3 951 4129

Israel, Bio-Rad Laboratories S.r.l., Via Cellini 18/A, 20090 Segrate, Milan • Phone +39 024 94 86 600 • Fax +39 02 2 1609399

Japan, Bio-Rad Laboratories K.K., Tennoz Central Tower 20F, 2-2-24 Higashi-Shinagawa, Shinagawa, Shinagawa

Singapore, Bio-Rad Laboratories (Singapore) Pte. Ltd., 3A International Business Park Road, #11-10/16, ICON @ IBP Tower B, Singapore 609935 • Phone +65 6415 3170 • Fax-South Africa, Bio-Rad Laboratories (Pty) Ltd., 34 Bolton Ave, Rosebank, Johannesburg • Phone +27 11 442 8508 • Fax +2711 442 8525

Spain, Bio-Rad Laboratories, S.A., C/ Caléndula, 95, Edificio M. Minipare II, El Soto de la Moraleja, 28109 Alcobendas • Phone +34 91 490 6580 • Fax +34 91 590 5211

Sweden, Bio-Rad Laboratories A.B., Solna Strandväg 3, SE-171 54 Solna, P.O. Box 1097, SE-172 22 Sundbyberg • Phone +46 844 98053 • Fax +46 8 55 51 27 80

Switzerland, Bio-Rad Laboratories AG, Pra Rond 23, CH-1785 Cressier • Phone +41 (0) 61 717 9555 • Fax +41 (0) 61 717 9555 • Fax +41 (0) 61 717 9555 • Fax +41 (0) 61 717 9550 • Fax +886 (2) 2578-7189 • Fax +886 (2) 2578-6890

Taliand, Bio-Rad Laboratories Ltd., 13t & 2nd Floor, Lumpini I Bidg., 239/2 Rajdemri Road, Lumpini, Pathumwan, Bangkok 10330 • Phone (662) 651 8311 • Fax (662) 651 8312


United Kingdom, Bio-Rad Laboratories Ltd., The Junction Station Road, Watford, Hertfordshire, WD17 1ET • Phone +44 (0) 1923 471301 • Fax +44 (0) 1923 471340

English • 2023-02 • 4030-00S

10/22

BIO-RAD Lyphochek® Assayed Chemistry Control, Levels 1 and 2

		Level 1 - 26491		Lev	rel 2 - 264	92
	Units	Mean	Range	Mean		Range
BIOSYSTEMS B400/A25/A15 (5) (continued)						E haz
Urea (Urease, UV) (4)	mg/dL	29.9	25.4 - 34.4	91.0	77.4	- 105
Uric Acid (Uricase, colorimetric)	mg/dL	4.91	4.17 - 5.65	8.58	7.29	- 9.87
ERBA XL SERIES (5)						
Albumin	g/dL	3.90	3.30 - 4.50	2.70	2.28	- 3.12
Albumin (India Market Only)	g/dL	3.96	3.36 - 4.56	2.69	2.30	- 3.08
Alkaline Phosphatase (IFCC Optimized) (2)	U/L	115	92.1 - 138	487	391	- 583
Alkaline Phosphatase (India Market Only) (2)	U/L	115	91.0 - 139	476	380	- 572
ALT/SGPT (2)	U/L	27.6	22.2 - 33.0	104	83.5	- 125
ALT/SGPT (Modified IFCC) (India Market Only) (2)	U/L	27.4	22.0 - 32.8	102	81.0	- 122
Amylase (2)	U/L	60.5	48.5 - 72.5	393	315	- 471
AST/SG0T (2)	U/L	38.2	30.7 - 45.7	204	162	- 246
AST/SGOT (Modified IFCC) (India Market Only) (2)	U/L	37.1	29.6 - 44.6	199	160	- 238
Bilirubin (Direct)	mg/dL	0.370	0.280 - 0.460	1.31	0.980	- 1.64
Bilirubin (Direct) (DCA)	mg/dL	0.390	0.300 - 0.480	1.65	1.23	- 2.07
Bilirubin (Total)	mg/dL	0.990	0.750 - 1.23	4.77	3.57	- 5.97
Bilirubin (Total) (DCA)	mg/dL	1.01	0.770 - 1.25	4.70		- 5.87
Calcium	mg/dL	9.94	8.44 - 11.4	13.4		- 15.5
Calcium (India Market Only)	mg/dL	9.21	7.83 - 10.6	12.3		- 14.1
Carbon Dioxide (CO2)	mEg/L	34.5	27.6 - 41.4	19.0		- 22.8
Chloride	mEq/L	107	96.0 - 118	93.0	P3+5/0001	- 102
Chloride (Mercuric Thiocyanate)	mEq/L	109	94.0 - 124	101		- 116
Cholesterol (HDL) (7)	mg/dL	67.2	53.7 - 80.7	23.9		- 28.7
Cholesterol (LDL)	mg/dL	149	119 - 179	67.6		- 81.1
Cholesterol (Total)	mg/dL	251	212 - 290	104		- 119
Cholinesterase (2)	U/L	7492	5995 - 8989	1131		- 1356
Creatine Kinase (CK) (2)	U/L	141	114 - 168	463		- 556
Creatinine (Alkaline picrate method)		2.59				- 6.88
Creatinine (Enzymatic)	mg/dL		2.08 - 3.10	5.74		
Creatinine (Enzymatic) Creatinine (Enzymatic) (India Market Only)	mg/dL	1.80	1.44 - 2.16	5.21		- 6.26
Gamma Glutamyltransferase (GGT) (2)	mg/dL	1.66		4.80		- 5.70
Glucose	U/L	66.3	53.1 - 79.5	167		- 200
Glucose (Hexokinase) (India Market Only)	mg/dL	91.7	77.9 - 106	304	259	120
Iron	mg/dL	85.4	72.5 - 98.3	285	243	
Iron (UIBC)	µg/dL	236	188 - 284	62.1		- 74.4
Lactate Dehydrogenase (LDH) (2)	µg/dL	63.3	50.7 - 75.9	126		- 150
Lipase (2)	U/L	333	267 - 399	888		- 1065
Lithium	U/L	43.1	34.4 - 51.8	57.7		- 69.1
	mEq/L	0.460	0.400 - 0.520	1.71		- 1.89
Magnesium	mg/dL	1.91	1.61 - 2.21	4.49		- 5.15
Phosphorus (India Market Only)	mg/dL	3.87	3.30 - 4.44	7.20		- 8.40
Phosphorus (New Formulation)	mg/dL	3.91	3.31 - 4.51	7.74		- 8.91
Potassium	mEq/L	3.61	3.25 - 3.97	5.49		- 6.03
Protein Serum (Total)	g/dL	6.94	5.89 - 7.99	4.75	4.03	- 5.47
Protein Serum (Total) (India Market Only)	g/dL	6.51	5.52 - 7.50	4.30	3.70	- 4.90
Sodium	mEq/L	140	126 - 154	123	110	- 135
riglycerides	mg/dL	186	159 - 213	96.1	81.7	- 111
riglycerides (India Market Only)	mg/dL	182	155 – 209	82.6	70.3	- 94.9
Irea (4)	mg/dL	33.8	28.7 - 38.9	103	88.0	- 118
Jric Acid	mg/dL	5.38	4.57 - 6.19	10.8	9.30	- 12.3



ASSESMENT OF INTER-LAB COMPARISION FOR LAB ANALYTES	NEXURE - 01 HEALTH HORIZON DIAGNOSTICS
	ANNEX

INTER-LAB COMPARISION:

DATE: 30/03/2023

Criteria: - One sample analyzed in the lab and same sample was send to NABL Accredited Lab for Inter-Lab Comparison.

Test Performed By: - MR. Santoch Hake

Performed By			Source of the local		
table	NO			1	
Acceptable	Yes		-	7	
Evaluation	Criteria %CV		5% or	±3SD	
Actual	Result			0.61	
STICS NABL	TED LAB RESULT	Sample - 02			
AG DIAGNOSTICS NABL	ACCREDITED LAB ANALYTE RESULT	Sample – 01 Sample - 02	0 00	92.0	
HORIZON	S ANALYTE	Sample - 02		-	
HEALTH HORIZON	DIAGNOSTICS ANALYTE RESULT	Sample – 01 Sample	0 00	72.0	
	ANALYTE		Serum	Chloride	

Health Horizon Diagnostics Chloride Sample 01 Result = 92.8

NABL Accredited AG Diagnostics Chloride Sample 01 Result = 92.0

Comparison Sample Mean = 92.4,

Comparison Sample SD = 0.56,

Comparison Sample CV = 0.61

ASSESMENT OF LOT TO LOT/BATCH TO BATCH VERIFICATION FOR BIOCHEMISTRY	DIAGNOSTICS ANNEXURE - 01 HEALTH HORIZON DIAGNOSTICS Page 2
	DIAGNOSTIC

Page 2 of 2

Note*: Evaluation Criteria referred from MHL EQAS Program PT Sample Participant Summary.

For Inter-Lab Comparison Chloride result evaluation acceptable range = 5 % CV is acceptable or ± 3SD

Remark:

VA

Shhaeemon 2023 Checked By: -

Technical Manager

Wil. Inter-lab comparison was evaluated within acceptable rangle. Remark:

Reviewed by: Nanager LabHead/ Quality Manager

Dr. Ankeeta Lahoti M.B.B.S., M.D. PATHOLOGY



Dr. Harshal Patil M.D. DNB PATHOLOGY

Lab ID

: 00466 /OPD

Patient Name

: MR. MOHAMMAD ISRAFIL

Age / Sex

: 75 Years / Male

Referred By

: APPLE HOSPITAL

Lab Regn Date & Time: 30-Mar-2023 13:42

Coll. Date & Time

:30-Mar-2023 13:42

Report Date & Time

:30-Mar-2023 15:13

Sample Type

: SERUM

Barcode

BIOCHEMISTRY.

Investigation	Result	Unit	Bio. Ref. Range
KIDNEY FUNCTION TEST			
Blood Urea	85.9	mg/dL	12.8-42.8
Method : Urease)			
Creatinine	1.17	mg/dL	0.6-1.3
Method : Enzymatic)			
Sr. Uric Acid	6.1	mg/dL	3.5-7.2
Method : (Uricase/Peroxidase)			
Test Done on Fully Automated EM 20	00 Biochemistry Analyzer		
ELECTROLYTES			
Sodium	121.0	mEq/lit	135-145
Potassium	5.47	mEq/lit	3.5-5.1
Chloride	92.8	mmol/L	98-107
est done on Easy Lite -Fully Automated	Electrolyte Analyser		3.5 5.5

Dr Ankeeta Lahoti **MD Pathology**



MOHAMMAD ISRAFIL

Ref.:Dr.-Sample Collected At:
Synergen Diagnostics

Unit 105, Sai Chambers, Wakadewadi,

Old Mumbai-Pune Highway, **Pune - 411003 Zone SHIVA**

REPORT

Age:75.00 Years Sex:MALE

SID: 122222693

Collection Date: 30-03-2023 08:24 PM Registration Date: 30-03-2023 08:24 pm

Report Date: 30-03-2023 08:59 PM

Test Description Clinical Chemistry:	Observed Value	Biological Reference Interval
Bilirubin-Total, serum by Diazo method	2.00	0.10 - 1.20 mg/dL Neonates : Upto 15.0 mg/dL
Bilirubin-Conjugated, serum by Diazo method Bilirubin-Unconjugated, serum by calculation Kindly correlate clinically and follow up.	<u>1.30</u> 0.70	Upto 0.5 mg/dL 0.1 to 1.0 mg/dL
Chloride, serum by IMT Indirect	92.00	98 to 107 mmol/Lt

End of Report

MC-3143

Page 1 of 1

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

Carrying forward Dr. Ajit Golwilkar's legacy of Over Four Decades DIAGNOSTICS

BE WELL


ए.जी डायग्नॉस्टिक्स प्रा. लि.

____ A.G Diagnostics Pvt. Ltd.

Dr. Awanti Golwilkar MB8S, MD (Pathology)

Dr. Shantanu Roy D.C.P.,D.N.B. (Path) Reg.No.-2013/02/0274 A.G Diagnostics Pvt. Ltd.

> Dr. Vinanti Golwilkar MBBS, MD (Pathology)



A.G Diagnostics Pvt. Ltd. a Neuberg associate Dr. Awanti Golwilkar
MBBS. MD (Pathology)

Dr. Vinanti Golwilkar

MBBS, MD (Pathology)

AGREEMENT FOR PROVISION OF DIAGNOSTIC LABORATORY SERVICES

This agreement for Provision of Diagnostic Laboratory Services is executed on 01-03-2023.

BY AND BETWEEN

A.G Diagnostics Private Limited, a company incorporated under the provisions of companies act 2013 & having its office at Nayantara, Bhandarkar Road Pune 411004 (hereinafter referred to as "**AGD**" which expression shall, unless repugnant to the context thereof, mean and include its legal representatives, partners, administrators and permitted assigns), represented through its authorised signatory Mr. Amol Deshmukh of the one part.

AND

Health Horizon Diagnostics — , whose details are specified under Annexure A (hereinafter referred to as the "Client" which expression shall, unless repugnant to the context thereof, mean and include its legal representatives, partners, administrators and permitted assigns) represented by Dr. Harshal Patil — of the other part. AGD & the Client hereinafter also be collectively referred to as "Parties" & individually as the "Party".

WHEREAS

- a. AGD is engaged in providing reliable, fast and affordable Pathology laboratory and wellness services to patients, clinicians & other laboratories in and around Pune. AGD has best of equipment, technology & manpower of international standards with a sound infrastructure and properly laid down systems. AGD is accredited by NABL through Certificate No. MC-3143.
- b. The Client after the mutual discussions between both the Parties has agreed to avail services of AGD. In furtherance of the same, the Parties are desirous of entering into this Contract to record the terms and conditions subject to which AGD shall provide its Services, and the Client shall pay the fees.

Therefore, it is agreed to record the understanding between the parties on the terms & conditions as set forth below:

1. SERVICES:

- 1.1 The Client hereby engages AGD to provide services listed in AGD's latest DOS and Annexure B.
- 1.2 AGD will provide the services as per its Directory of Services (DOS). Changes if any shall be communicated to the Client 15 days in advance in writing. Client will make the necessary changes to its records & shall consider the changes as final.
- 1.3 Client acknowledges that under unavoidable / unforeseen circumstances AGD may discontinue any service or change the method of testing without prior intimation to the Client. However, to minimize the impact on the patient / healthcare, the same will be intimated to the Client at earliest.
- 1.4 If the samples are collected at the Client's premises, AGD shall offer Logistics support as described through Clause 2.

2. LOGISTICS:

- 2.1 AGD shall arrange for the pickup of samples from the Client's premises on all the weekdays during working hours of AGD.
- 2.2 AGD shall not provide logistic services on Sundays & public holidays.

2 J. V3 bZ6 Agreement – Labs and Hospitals

Expertise Based On A Legacy Of Over Neur Decades

A.G Diagnostics Pvt. Ltd., Registered Office: Nayantara, Bhandarka Road, Pune Tel: +91 20 6763 6763 | E-mail: info@agdiagnostics.com | www.agdiagnostics.com | www.agdiagnosti

CIN - U74999PN2017PTC172845

- 2.3 The representatives of both the parties will mutually decide on the periodicity of the sample pick up based on the workload.
- 2.4 AGD shall ensure that the samples are transported to the laboratory from the Client's premises in optimum storage conditions. It is responsibility of the Client to ensure packing in such a manner to ensure sample integrity during transit.
- 2.5 In event of sample loss due to unavoidable circumstances, AGD shall not be held responsible.
- 2.6 The responsibility for appropriate sample collection as per test requirements and labelling after correct patient identification and providing relevant clinical history in the Test Requisition Form remains with the client.

3. REPORTS:

- 3.1 AGD shall deliver the reports to the Client as per the Turnaround time committed in the DOS, however in unforeseen circumstances reports may be delayed. AGD agrees to ensure that the delay is minimal & the Client shall not raise any claim for refund or initiate any action against AGD.
- 3.2 Mode of delivery: It is agreed between the parties that preferred mode of delivery is Auto email services by AGD wherein the Client shall provide a correct email id on which reports shall be emailed by AGD. The responsibility towards appropriate access to this email id on the Client's end, remains with the Client. The email id for providing auto email provided by Client to AGD is as mentioned in Annexure A.
- 3.3 The hard copy shall be delivered by the Logistics person if the Client desires so.
- 3.4 It is further agreed between the parties that Auto Email Service shall not be available for tests inclusive of but not limited to where reports have graphics, attachment of certain kinds, two signatures etc. Annexure C includes the list of few such tests.

4. COMPENSATION FOR SERVICES:

- 4.1 The Invoice shall be generated Monthly _based on test charges agreed upon through Annexure B and will be sent to the Client at its office mentioned in this agreement unless otherwise specified & agreed upon.
- 4.2 Clients shall check the Invoice & intimate any discrepancy to AGD within 5 working days. AGD will verify the same & shall amend the invoice accordingly, if necessary & resubmit to the Client. However, if the discrepancy is not reported, Client agrees to pay the entire invoice amount.
- 4.3 Client agrees to pay the invoice amount in 8 working days. Under any circumstances Client shall not withhold any payment. If there is any discrepancy, Client shall release remaining amount immediately & shall release the discrepant amount upon successful resolution of the issue reported, in any case not later than 30 days.

4.4 PAYMENT MODE:

- 4.4.1 Cheque/Demand Draft (DD): The Payment in favour of "A.G Diagnostics Pvt. Ltd".
- 4.4.2 **NEFT**: Details as below:

A/C Name: A.G Diagnostics Pvt. Ltd.

Bank Name: ICICI Bank Ltd Branch: Bhandarkar Road-Pune A/C No.: 624005020746

RTGS/NEFT IFSC code: ICIC0006240

MICR: 411229006

- 4.4.3 Cash: Clients shall prefer any of the above modes of payment & avoid cash payment. However, if such need arises the Client shall intimate AGD in writing. AGD shall not be responsible for any cash payments released without such intimation.
- 4.5 If the Client fails to pay within 15 days of receipt of invoice, AGD reserves the right to hold the services till the outstanding amount is cleared. In case of non-payment within agreed upon duration, AGD will charge interest @ 1.25% per month from the due date.
- 4.6 AGD PAN number is AAQCA0978E



5. DURATION/TERM:

5.1 This agreement shall commence from 01-03-2023 & will be in force up to 28-02-2026 for a period of 36 months.

6. RENEWAL:

6.1 The agreement may be renewed for a further period on mutual terms & conditions as agreed between the parties.

7. TERMINATION:

7.1 Either party can terminate this agreement by giving clear 30 days' notice in writing. Either party shall also be entitled to terminate this Agreement with immediate effect if any breach of terms and conditions contained in this agreement. Before terminating this agreement both parties agree to settle all dues towards each other.

8. CONFIDENTIALITY:

8.1 Either party shall not disclose and /or divulge to any person/s and /or companies any information related to the terms & conditions of this agreement. AGD agrees not to disclose to any third party any information with regards to the tests conducted by AGD.

9. **DISPUTES & ARBITRATION**:

- 9.1 If any dispute or difference of any kind whatsoever shall arise between the Parties in connection with or arising out of this agreement whether before or after the termination or breach of this agreement the Parties shall promptly & in good faith negotiate to find an amicable resolution & settlement.
- 9.2 In the event no amicable resolution or settlement is reached within a period of 30 days such a dispute or difference shall be referred to a mutually acceptable single arbitrator under the provisions of the Indian Arbitration & conciliation Act 1996. The arbitration proceedings shall be held in Pune.
- 9.3 Notwithstanding anything contained herein, the parties shall have the right to institute legal proceedings to prevent any such continuing breach of provisions of this Agreement to seek specific relief & the courts in Pune shall have exclusive jurisdiction on any matter arising out of this Agreement.

10. MISCELLANEOUS

- 10.1 **Intellectual Property Rights.** All intellectual property rights belonging to a Party prior or after the execution of this agreement shall remain vested in that Party. None of the intellectual property rights in either Party's trademarks and/or brands shall be used by the other Party for any purpose, without such other Party's prior written consent.
- 10.2 Entire Agreement. This agreement supersedes any earlier contracts, communications that may have been entered into between the Parties on the said subject matter. All the Annexures which are mentioned in this agreement, shall be treated as integral part of this agreement. It is clarified that AGD is entitled to amend the AGD DoS from time to time at its sole discretion. In the event AGD amends the DoS such updated AGD DoS shall be deemed to be incorporated into this Contract by reference and such amended AGD DoS shall be made available to the Client.



Client Initials

10.3 **Force Majeure.** If the compliance of its obligations under this Contract by either Party is delayed, prevented, restricted or interfered with by reason of Force Majeure then the Party so affected, upon giving prompt written notice to the other Party, shall not be liable for non-performance of such obligations.

IN WITNESS OF the Parties hereto have executed this Agreement on the date mentioned above

For and on behalf of the Client:

Name: Dr. Harshal Patil

Title: Director

For and on behalf of AGD:

Name: Mr. Amol Deshmukh

Title: General Manager



2.1.1. V1

ANNEXURE A

Client Details

Details of the Client:

SI. #	Particulars Required	Details	
1	Name of the Client	Health Horizon Diagnostics	
2	Client Constitution	(Proprietorship/Partnership/ Private Ltd Co/Public Ltd Co)	
3	Trade Licence No/CIN	Please provide Trade Licence No or CIN	
4	Permanent Account No.		
5	Name(s) of Proprietor / Partners / Directors	1. Dr. Harshal Patil 2. Dr. Ankeeta Lahoti 3. 4. 5.	
6	Email Id of Proprietor / Partners / Directors	1. hhdiagnostics@gmail.com 2. 3. 4. 5.	
7	Nature of Business (Laboratory/Hospital/Others)	Laboratory	
8	Office Address	Flat No. 401 & 402, CTS No.364,365/13,FP No.713, 714/13, Varun Capital, Shivaji Nagar,Pune-411005	
9	Contact Person Name	Mr. Dhananjay Abhang	
10	Contact Person Phone No.	8070000444	
11	Contact Person e-mail ID for auto email services	synergendiagnostics@gmail.com	
12	Authorised Signatory Name	Dr. Harshal Patil	
13	Authorised Signatory Designation	Director	
14	Authorised Signatory email address	hhdiagnostics@gmail.com	
15	Bank details from where payments will be made to AGD	Bank Name: Account Type: Bank Address: IFSC Code:	



2.1.2. V1

ANNEXURE B

Commercials

Subject to Clause 1, the term 'Services' shall mean any of the services detailed in column (B) hereto, which have been agreed to be provided by AGD in relation to the Samples. Also, subject to Clause 4.1, the term 'test charges' in relation to a Service shall mean the cost prescribed against such Service in column (C) below:

S.	Services	Test Charges
No.	(B)	(C)
1)	All types of medical diagnostic laboratory services currently being provided by AGD. A list of all the tests currently being provided by AGD is provided in latest AGD DoS.	List Price as per AGD Directory of Services & discount structure as given below

Standard Discount Structure:

Sr. No	Category of Tests	Discount % on List Price in DoS
1	A3	30 %
2	A4	20 %
3	A5	10 %
4	A6	0 %

Special Discount:

Sr. No	Test	Test Charges (₹)	Discounted Charges (₹)
1	FSH	500	150
2	LH	500	150
3	Beta HCG	840	200
4	E2- Estradiol	700	200
5			200
6			
7	1		
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20		1	

AGD Initial PUNE

2.1.3 V2.

ANNEXURE C

List of Tests excluded from Auto Email services.

Sr. No	Name of Test
1	Histopathology Reports
2	Double Marker Test- First Trimester
3	Triple Marker Test- Second Trimester
4	Quadruple Test
5	Hemoglobin Electrophoresis
6	Protein Electrophoresis
7	Immunofixation Electrophoresis





HEALTH HORIZON DIAGNOSTICS

METROPOLIS HEALTHCARE LTD.

EXTERNAL QUALITY ASSURANCE SERVICE

(MHL EQAS PROGRAM)

FOR
UNACCEPTABLE RESULTS OF

BILIRUBIN DIRECT TEST

HHD-QSP/009/00



FORMAT OF EXTERNAL QUALITY CONTROL/ PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS

ANNEXURE-01

HEALTH HORIZON DIAGNOSTICS

Type of Ev	aluation: E	external Qualit	y Control / P	roficie	ency Testing (PT)	Sample 🗓
Other [] (S	Specify):	_				
Evaluation	Date: 2	5 01 202	3			
Investigation	on: Hem	atology 🗌 Bio	chemistry U	Urin	e Serology .	Immunology
Other (Spe	ecify):					
Unacceptal	ble Analyte	e/ Parameter:				
IMHL	EGAS	Sample	NO:02	1.1	Bilirubin	Direct.

Description/Error/ Reason/ Remark:

MHL EARS: Bilirubin Direct.

Sample No: 02 = SDI 2-Score = -2.32

Warning alert flag.

Investigations (Root Cause Analysis):

Phase	Commonest Reasons	Tick Cross
Pre-Analytical Phase	1. Missed Test Requisition Form (TRF)	
	2. Incorrect sample identification	
	3. Incorrect sample tube	
	4. Sample from IV running area	
	5. Delay in sample transportation	
	6. Insufficient samples	
	7. Sample mix-ups	
	8. Tube broken in centrifuge	
	9. Wrong timing for Collection	
	10. Invalid Specimen: Haemolysed Sample, Lipemic Sample and Icteric Sample	
	11. Software errors	
Analytical Phase	1. Instrument not calibrated properly	
	2. Specimen mix-up	
	3. Inadequate specimen	
	4. Presence of interfering substances	
	5. Wrong analytical method	
	6. Lack of precision	
Post-Analytical Phase	1. Wrong patient identification	
	2. Report not legible	
	3. Report delayed	
	4. Transcriptional error	
	5. Specificity of the test not understood	
	6. Previous values are not available for comparison	



FORMAT OF EXTERNAL QUALITY CONTROL/PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS

ANNEXURE-01

HEALTH HORIZON DIAGNOSTICS

Root Cause Analysis: MHL EGAS Brock	remistry sample No:02 Bilirubin					
Nivert tret VIII MIN EDRA EM.	211 Anouyse . In We Checkey					
I s s laws a Bulatily Country	the dille hingh that was will					
1 1 1 11 11	el blo VIIIII TILL VII EUT					
specimen handling was cross	checked as per our as r					
"Handling proficiency testing	and External actually 1884 1009 100)					
Corrective Action: Corrective action	checked as per our asp and External quality Assurance sample (HHB-asploog 100) taken on date 25/01/23					
We checked Internal aua	Lity control record on date					
17/01/2023 . [al result was a	vithin range. Also the preventive					
maintenance of the instrumen	lify control record on date within range. Also the preventive I was done by the service engineer.					
Preventive Action: For Analyser.	ERBA EM-200 on date 30/01/23					
Aftermaintenance Iac pe						
range.						
Conclusion serum Bilirubin Di	rect had a PT outlier,					
2+ was a warning signal and accordingly corrective						
and preventive action was taken.						
Attachment (Attach result form and assessment details):						
Attached Scan copy!						
1) Instrument Service Report						
2) Internal ac data on date						
17/01/2023 & 30/01/2023 for						
Bilirubin Direct Test						
3) IGC BIORAD Value sheet						
Col No. 26490 Level-02-26492						
Comment: Nil						
2) [G(BIORAD Value sheet Col No. 26490 Level-02-26492 Comment: Nil Ymanyor 3010112023						
Recorded By : Sign / Date (Laboratory Manage	er /Authorized trained person)					
	-					
Malah 30/01/2	23					
Verified By: Sign / Date (Laboratory Director/	Authorized trained person)					
ormed by . Sign / Date (Laboratory Director).	raumonized trained person)					




EQAS CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS

HEALTH HORIZON DIAGNOSTICS

Page 1 of 1

SR.	LIST OF DOCUMENTS
NO	
01	Annexure: 01: Instrument service Report
02	Annexure: 02: Internal Quality Control Data Date of 17/01/2023 & 30/01/2023
03	Annexure: 03: Internal Quality Control BIO-RAD Value Sheet Lot No. 26490, Level 01:26491 & Level 02: 26492



IIKARDADIA


TECHNICAL SERVICE RI	EPORT No. 101764	DATE: 2. [0.1] 23
CUSTOMER DETAILS	INSTRUMENT DETAIL	
NAME: Heath	MODEL EMILE	[] WARRANTY [] RER
ADDRESS		ET AME CHARGED CALL
Hemon		TYPE OF CALL
Diegochs Pare	CALL DETAILS	THE A DEM VISIT (1/H) HETV
To the state of th	COMPLAINT RECD.	APPLICATION SUPPORT
TEL NO.	JOB COMPLETED	DREAKDOWN
NAME OF THE OPERATOR	RESPONSE TIME TELS	DOWN TIME
PROBLEM REPORTED		COUNTER READING
OBSERVATIONS:	50	
	presentive	Maintenance
ACTION TAKEN:		
	Done pu as 1	re- pootora
-	clear both of	urber Pepland larp
Policyd	laundry fublings	alex loop cooling path
BRAND OF REAGENT USED:	NEUTRAL EARTH	VOLET LINE EARTH VOLET
		TO BE FILLED IN BY CUSTOMER PREVENTIVE MAINTENANCE CARRIED OUT
FOLLOWING PARTS HAVE BEEN RE FOLLOWING PARTS NEED TO BE R	PLACED	SATISFACTORILY. FAULT RECTIFIED & INSTRUMENT IS
NO. DESCRIPTION	OTY COST TOTAL	WORKING SATISFACTORILY WE HEREBY APPROVE RS. FOR
		PARTS
		Gohans (IF ANY)
		Uphang_
		wate, customeres signature i
TOTAL Rs.		30/11/20 NAME:
INVOICE NO.: FOLLOW-UP ACTION (Required if any)	DATE	BRANCH H.O.
		RECEIVED ON :
ENGINEER'S APPLICATION SPECIALS		OB CARD NO. :
ENGINEER'SIAPPLICATION SPECIALITIME: 12 Fm to 2 Pm NAME: 7	mout kulkoni	
THE RESERVE THE PARTY OF THE PA	随着的,是1000年上午100000000000000000000000000000000	for head, lamp, labing, paper rolls etc. & breakable parts are 1 Will alice the charged in every case.
The second section of the second seco	SENTINEGAL SENVICE), MI	RN. IN CASE YOU HAVE ANY SUGGESTIONS JMBAILTEL. 4030 9000
TRANSASIA BIO-MEDICALS LTI Head Office - Transasia House, 8, Chandiya	Studio Road, Andhen (E), Mumbel -	400 072, Tel.: (022) 4030 9000 Fax: (022) 2857 3030
hoore Tel. (6731) 403 3948 Ch	Whatsapp No.: 8451048434, SMS	No. : 9212433444 Kolkata : Tel (033) 2215 7839 Fax : 2215 8035
Lucknow Tel.: (0522) 443 0900 Put Changigath Tel.: (0172) 464 3837 Hyd	terebad : Tel. : (020) 2615 2658 Serebad : Tel. : (040) 4430 9000	Dehi : Tel.: (011) 2576 5451/2573 2223 Ahmedabad : Tel./Fax : (079) 02640 7030/4032 1903
Patoa Tel.: 77669 00553 Oh	wehati : Tel.: 91369 50480 dtack : Tel.: (9671) 232 4555	Bangalore ; Tel:/Fax (080) 2558 8044
Knobs TeL (0484) 402 0511 Flui	Tel. : (6838) 485 0900	ZONE COPY

DOC NO : 8000-4067-55-8

www.transasia.co.in

ISS 13485 & ISS 8001 Carried Ca

(Erba



Internal quality control BIO-RAD Level - 2

Result Reprint

Report Type : Controls

# LS	* Lot *	Consumable	Test	Result Unit	Flag	Curve #	Result Date	Mean	SD	Interval (3SD)
-	26492	BIORAD LEVEL 2	SGPTD	107.9 U/L		84511	17-Jan-2023 10:43:24	102.000	6.800	81.6 - 122.4
2	26492	BIORAD LEVEL 2	SGOTD	196.9 U/L		84512	17-Jan-2023 10:43:42	199.000	12.990	160.03 - 237.97
ന	26492	BIORAD LEVEL 2	ALPU	449 U/L	-1SD	84513	17-Jan-2023 10:44:00	487.000	32.000	391 - 583
4	26492	BIORAD LEVEL 2	BID	1.54 mg/dl	+2SD	84514	17-Jan-2023 10:44:18	1.310	0.110	0.98 - 1.64
O	26492	BIORAD LEVEL 2	ВП	5.19 mg/dl	+1SD,HV!	84515	17-Jan-2023 10:44:36	4.770	0.400	3.57 - 5.97
Ø	26492	BIORAD LEVEL 2	UREA	95.9 mg/dl	-1SD	84516	17-Jan-2023 10:44:54	103.000	5.000	88 - 118
7	26492	BIORAD LEVEL 2	CRENZ	5.44 mg/dl		84517	17-Jan-2023 10:45:12	5.210	0.350	4.16 - 6.26
00	26492	BIORAD LEVEL 2	GLU	302.0 mg/dl		84518	17-Jan-2023 10:45:30	304.000	15.000	259 - 349
0	26492	BIORAD LEVEL 2	TRIG	92.5 mg/dl	HV!	84519	17-Jan-2023 10:45:48	96.100	4.960	81.22 - 110.98
0	26492	BIORAD LEVEL 2	CHOL	lb/gm 76	-1SD	84520	17-Jan-2023 10:46:06	104.000	5.000	89 - 119
7	26492	BIORAD LEVEL 2	HDLC	24.3 mg/dl		84521	17-Jan-2023 10:46:24	23.900	1.600	19.1-28.7
12	26492	BIORAD LEVEL 2	UA	11.1 mg/dl		84522	17-Jan-2023 10:46:42	10.800	0.500	9.3 - 12.3
63	26492	BIORAD LEVEL 2	ALB	2.72 g/dl		84523	17-Jan-2023 10:47:01	2.690	0.130	2.3-3.08
4	26492	BIORAD LEVEL 2	PRO	4.67 g/dl		84524	17-Jan-2023 10:47:19 4.750	4.750	0.240	4.03 - 5.47

Dorne By o- Janhaul

checked 187!-

Internal quality control BIORAD Level-2.

Result Reprint

Report Type : Controls

Sone 137! -

Checked BT: Showing






Lyphochek® Assayed Chemistry Control Levels 1 and 2



C-310-5 Level 1 12 x 5 mL C-315-5 Level 2 12 x 5 mL 313X MiniPak 2 x 5 mL







LOT

26490

Level 1 26491 Level 2 26492



https://www.myeinserts.com/26490

INTENDED USE

Lyphochek Assayed Chemistry Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.

SUMMARY AND PRINCIPLE

The use of quality control materials is indicated as an objective assessment of the precision of methods and techniques in use and is an integral part of good laboratory practices. Multiple levels of control are available to allow monitoring of the test system's reliability.

For customers in Germany: Quality control materials are required for assessment of laboratory performance as described in the "Guideline for Quality Assurance of Medical Laboratory Examinations following the German Medical Association" (Rili-BÄK regulation).

REAGENT

This product is prepared from human serum with added chemicals, purified biochemical material (tissue extracts of human and animal origin), therapeutic drugs, stabilizers and preservatives. This product is provided in lyophilized form for increased stability.

STORAGE AND STABILITY

This product will be stable until the expiration date when stored unopened at 2 to 8°C.

Reconstituted and Refrigerated: After reconstituting and storing tightly capped at 2 to 8°C, this product will be stable as follows:

- All analytes: 7 days

Except:

 - T3 (Free), Acid Phosphatase (Total) and Prostatic Acid Phosphatase (PAP): 3 days

Reconstituted and Frozen: When reconstituted and stored tightly capped at -10 to -20°C, this product will be stable as follows:

- All analytes: 30 days

Except:

Tobramycin: 20 days
T3 (Free): 10 days

Once thawed, do not refreeze this product. Discard the remaining material. This product is shipped under ambient conditions.

PROCEDURE

This product should be treated the same as patient specimens and run in accordance with the instructions accompanying the instrument, kit, or reagent being used.

Using a volumetric pipet or equivalent, reconstitute each vial with 5.0 mL of distilled or deionized water. Replace the stopper and allow this product to stand for approximately 20 minutes swirling occasionally.

Before sampling, gently swirl the vial several times to ensure homogeneity. If performing trace metal analysis, do not mix by inversion. After each use, promptly replace the stopper and return to the appropriate storage condition. Dispose of any discarded materials in accordance with the requirements of your local waste management authorities. In the event of damage to packaging, contact the local Bio-Rad Laboratories Sales Office or Bio-Rad Laboratories Technical Services.

LIMITATIONS

- 1. This product should not be used past the expiration date.
- If there is evidence of microbial contamination or excessive turbidity in the reconstituted product, discard the vial.
- 3. This product is not intended for use as a standard.

WARNING

A Biological source material. Treat as potentially infectious.

Each human donor unit used to manufacture this product was tested as required by FDA accepted methods. Tests results were non-reactive or negative for evidence of infection due to Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV). This product may also contain other human source materials for which there are no approved tests. In accordance with good laboratory practice, all human source material should be considered potentially infectious and handled with the same precautions used with patient specimens.

Safety Data Sheet (SDS) available for professional users on www.bio-rad.com.

SPECIFIC PERFORMANCE CHARACTERISTICS

This product is a freeze-dried product manufactured under rigid quality control standards. To obtain consistent assay values, the control requires proper storage and handling as described.

ASSIGNMENT OF VALUES

The mean values and corresponding ±3SD ranges in the Assignment of Values Data Charts (available separately) were derived from replicate analyses and are specific for this lot of product. Data from Unity™ Interlaboratory Program are included in the determination of some ranges. The tests listed were performed by the manufacturer and/or independent laboratories using manufacturer supported reagents and a representative sampling of this lot of product. It is recommended that each laboratory establish its own acceptable ranges and use those provided only as guides. Laboratory established ranges may vary from those listed during the life of this control. [Customers in Germany have to follow the requirements as described in the Rili-BÄK regulation.] Variations over time and between laboratories may be caused by differences in laboratory technique, instrumentation and reagents, or by manufacturer test method modifications.

Unity™ Interlaboratory Program is a proprietary Bio-Rad software program holding more than 2 billion QC data points from thousands of laboratories.

INSTRUCTIONS FOR OBTAINING THE DATA CHARTS

The Data Charts are available through the Internet, at www.myeinserts.com/26490. Follow the directions at the website to receive email notifications of insert updates. Alternate methods for receiving data charts are available by contacting your local Bio-Rad Laboratories Office.



UNITED STATES, Bio-Rad Laboratories 9500 Jeronimo Road, Irvine, CA 92618



FRANCE, Bio-Rad I Raymond Poincare, 92430 Mames-la-Coquette Phone (33) 1-4795-6000 / Fax:(33) 1-4741-9133



SWITZERLAND, DiaMed GmbH Pra Rond 23, 1785 Cressier FR





SWITZERLAND, Bio-Rad Laboratories AG Pra Rond 23, 1785 Cressier FR

BIO-RAD

Laboratories, Inc.

Clinical Diagnostics Group

9500 Jeronimo Road Irvine, California 92618 (800) 854-6737 FAX (949) 598-1550 bio-rad.com/qualitycontrol

Technical Service: (800) 854-6737

Australia, Bio-Rad Laboratories Pty. Ltd., v1A, 62 Ferndall Street, South Granville, New South Wales 2142 * Phone +61 (2) 9314 2000 * Fax +61 (2) 9314 2868
Austria, Bio-Rad Laboratories Clas...m.b.H., Hummelgasse 86/3-6, A-1130 Vienna * Phone +43 (0) 1 077 78 01 9 * Fax +45 (0) 1 870 56 29
Bolglum, Bio-Rad Laboratories N.V., Winnighana 9, BE-9140 Temse + Phone +32 (0) 3 170 53 00 * Fax +32 (0) 1 870 53 00 * Fax +36 1 83 072 China, Bio-Rad Laboratories Ltd., 2403 Gainette Street, Mortrial, Québec 4HA (ES P * Phone +15 113 344 572 * Fax + 15 14 334 0372 China, Bio-Rad Laboratories (Shanghal) Co., Ltd. Room 601, Allian Plaza, No. 168 Jingshou Road, Yangpu District, Shanghal 200082 * Phone +86 21 6169 8509 * Fax +86 21 6169 8599 Czech Republic, Bio-Rad 260, st. co., Piktoria 1737/11a, 14000 Pragua 4 * Phone +420 614 31 660 Dommark, Bio-Rad Laboratories (Shanghal) Co., Ltd. Room 601, Allian Plaza, No. 168 Jingshou Road, Yangpu District, Shanghal 200082 * Phone +86 21 6169 8599 Czech Republic, Bio-Rad 260, st. co., Piktoria 1737/11a, 14000 Pragua 4 * Phone +420 614 31 660 Dommark, Bio-Rad Laboratories (Shanghal) Co., Ltd. Room 601, Allian Plaza, No. 168 Jingshou Road, Yangpu District, Shanghal 200082 * Phone +86 21 6169 8599 Czech Republic, Bio-Rad 260, Kutomotia 16 Fac Pho380, Helanik * Phone +36 98 804 22 00 1 Finland, Bio-Rad Laboratories (Smbt, Kangbalenstafa 12, D-85622 Feldikrichen, Munich * Phone +43 61 610 00 * Fax +45 45 21 0 01 Finland, Bio-Rad Laboratories (Ed.), Lin 1101, Lin 1101, Lin 1101 China Commarcial Centra, 25 68 602 * Fax +30 210 7777436 * Fax +30 210 7777476 * Hong Kong, Bio-Rad Laboratories (Ld., Lin 11101, Lin 1101) China Commarcial Centra, 25 68 602 * Fax +30 210 7777436 * Fax +81 3 463 8481 Korea, Bio-Rad Laboratories (Ld., Lin 11101, Lin 2000) Sargan, Bio-Rad Laboratories (Ld., Lin 11101, Lin 2000) Sargan, Bio-Rad Laboratories (Ld., Lin

English • 2023-02 • 4030-008

BIO-RAD Lyphochek® Assayed Chemistry Control, Levels 1 and 2

INICT	DIES	REAFF	141
HOM	nuiv	TENT	117

NSTRUMENT (1)		Level 1 - 26491		Level 2 - 26492	
	Units	Mean	Range	Mean	Range
BIOSYSTEMS B400/A25/A15 (5) (continued)					
Urea (Urease, UV) (4)	mg/dL	29.9	25.4 - 34.4	91.0	77.4 – 105
Uric Acid (Uricase, colorimetric)	mg/dL	4.91	4.17 - 5.65	8.58	7.29 - 9.87
ERBA XL SERIES (5)					
Albumin	g/dL	3.90	3.30 - 4.50	2.70	2.28 - 3.12
Albumin (India Market Only)	g/dL	3.96	3.36 - 4.56	2.69	2.30 - 3.08
Alkaline Phosphatase (IFCC Optimized) (2)	U/L	115	92.1 - 138	487	391 - 583
Alkaline Phosphatase (India Market Only) (2)	U/L	115	91.0 - 139	476	380 - 572
ALT/SGPT (2)	U/L	27.6	22.2 - 33.0	104	83.5 - 125
ALT/SGPT (Modified IFCC) (India Market Only) (2)	U/L	27.4	22.0 - 32.8	102	81.0 - 122
Amylase (2)	U/L	60.5	48.5 - 72.5	393	315 - 471
AST/SGOT (2)	U/L	38.2	30.7 - 45.7	204	162 - 246
AST/SGOT (Modified IFCC) (India Market Only) (2)	U/L	37.1	29.6 - 44.6	199	160 - 238
Bilirubin (Direct)	mg/dL	0.370	0.280 - 0.460	1.31	0.980 - 1.64
Bilirubin (Direct) (DCA)	mg/dL	0.390	0.300 - 0.480	1.65	1.23 - 2.07
Bilirubin (Total)	mg/dL	0.990	0.750 - 1.23	4.77	3.57 - 5.97
Bilirubin (Total) (DCA)	mg/dL	1.01	0.770 - 1.25	4.70	3.53 - 5.87
Calcium	mg/dL	9.94	8.44 - 11.4	13.4	11.3 - 15.5
Calcium (India Market Only)	mg/dL	9.21	7.83 - 10.6	12.3	10.5 - 14.1
Carbon Dioxide (CO2)	mEg/L	34.5	27.6 - 41.4	19.0	15.2 - 22.8
Chloride	mEq/L	107	96.0 - 118	93.0	83.7 - 102
Chloride (Mercuric Thiocyanate)	mEq/L	109	94.0 - 124	101	86.0 - 116
Cholesterol (HDL) (7)	mg/dL	67.2	53.7 - 80.7	23.9	19.1 - 28.7
Cholesterol (LDL)	mg/dL	149	119 - 179	67.6	54.1 - 81.1
Cholesterol (Total)	mg/dL	251	212 - 290	104	88.0 - 119
Cholinesterase (2)	U/L	7492	5995 - 8989	1131	906 - 1356
Creatine Kinase (CK) (2)	U/L	141	114 - 168	463	370 - 556
Creatinine (Alkaline picrate method)	mg/dL	2.59	2.08 - 3.10		
Creatinine (Enzymatic)				5.74	4.60 - 6.88
Creatinine (Enzymatic) (India Market Only)	mg/dL	1.80	1.44 - 2.16	5.21	4.16 - 6.26
Gamma Glutamyltransferase (GGT) (2)	mg/dL U/L	66.3	1.33 - 1.99	4.80	3.90 - 5.70
Glucose			53.1 - 79.5	167	134 - 200
	mg/dL	91.7	77.9 - 106	304	259 - 349
Glucose (Hexokinase) (India Market Only)	mg/dL	85.4	72.5 - 98.3	285	243 - 327
ron	μg/dL	236	188 - 284	62.1	49.8 - 74.4
ron (UIBC)	μg/dL	63.3	50.7 - 75.9	126	102 - 150
actate Dehydrogenase (LDH) (2)	U/L	333	267 - 399	888	711 - 1065
ipase (2)	U/L	43.1	34.4 - 51.8	57.7	46.3 - 69.1
ithium	mEq/L	0.460	0.400 - 0.520	1.71	1.53 - 1.89
Magnesium	mg/dL	1.91	1.61 - 2.21	4.49	3.83 - 5.15
Phosphorus (India Market Only)	mg/dL	3.87	3.30 - 4.44	7.20	6.00 - 8.40
Phosphorus (New Formulation)	mg/dL	3.91	3.31 - 4.51	7.74	6.57 - 8.91
otassium	mEq/L	3.61	3.25 - 3.97	5.49	4.95 - 6.03
rotein Serum (Total)	g/dL	6.94	5.89 - 7.99	4.75	4.03 - 5.47
rotein Serum (Total) (India Market Only)	g/dL	6.51	5.52 - 7.50	4.30	3.70 - 4.90
odium	mEq/L	140	126 – 154	123	110 – 135
riglycerides	mg/dL	186	159 – 213	96.1	81.7 - 111
riglycerides (India Market Only)	mg/dL	182	155 - 209	82.6	70.3 - 94.9
Irea (4)	mg/dL	33.8	28.7 - 38.9	103	88.0 - 118
Jric Acid	mg/dL	5.38	4.57 - 6.19	10.8	9.30 - 12.3